Pfizer – Page 4

Pfizer Expands Collaboration with Flagship Pioneering, Adding Ampersand Biomedicines and Montai Therapeutics

5 months ago talkbio0Tagged Ampersand, Biomedicines, Drug Development, Flagship, Montai, Non-Small Cell Lung Carcinoma, Obesity, Pfizer, Pioneering, strategic partnership

Pfizer, Flagship Pioneering, Ampersand Biomedicines, Montai Therapeutics, strategic partnership, drug development, obesity, non-small cell lung cancer

Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development

5 months ago talkbio0Tagged Boshoff, Changing, Chris, Leadership, Mikael, Neoplasms, Pfizer, President brand of dental material, R&D, Research and Development, Scientific Officer

Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D

Angela Hwang Joins Flagship Pioneering as CEO-Partner and CEO of Metaphore Biotechnologies

5 months ago talkbio0Tagged Appointments, Biotechnology, Flagship, Hwang, Leadership, Metaphore, Pfizer, Pioneering

Angela Hwang, Flagship Pioneering, Metaphore Biotechnologies, Pfizer, Biotechnology, Leadership Appointment

Pfizer Weighs Sale of Hospital Drugs Unit Amid Activist Pressure

5 months ago talkbio0Tagged activist investor, Goldman Sachs, hospital drugs unit, Pfizer, Sales - occupational activity, Starboard Value

Pfizer, hospital drugs unit, sale, activist investor, Starboard Value, Goldman Sachs

GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others

5 months ago talkbio0Tagged AbbVie, AppTec, Bio, Biotechnology, Drug Industry, lobbying, Pfizer, SmithKline Beecham, Takeda, TNFRSF19 gene, UCB, WuXi

GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying

Biotech Layoffs Continue in 2024: Spero and Pfizer Among Latest to Cut Workforce

6 months ago talkbio0Tagged Biotech Layoffs, Drug Industry, layoffs, Pfizer, Spero

Biotech layoffs, Spero, Pfizer, workforce reduction, 2024 layoffs, pharmaceutical industry, job cuts.

Pfizer Boosts Revenue Forecast by $1.5 Billion Amid Paxlovid Rebound, Despite Criticism from Starboard

6 months ago talkbio0Tagged COVID19 (disease), financial performance, Paxlovid, Pfizer, Starboard

Pfizer, revenue outlook, Paxlovid, Starboard, pharmaceuticals, COVID-19, financial performance

GSK’s Arexvy RSV Vaccine Shows Promise in Younger Adults, Following Pfizer’s Approval

6 months ago talkbio0Tagged Abrysvo, Arexvy, Pfizer, Respiratory syncytial virus, Respiratory Tract Diseases, SmithKline Beecham, Vaccines, younger adults

GSK, Arexvy, RSV vaccine, younger adults, Pfizer, ABRYSVO, respiratory syncytial virus, lower respiratory tract disease

Pfizer Secures FDA Approval to Expand RSV Vaccine Abrysvo for High-Risk Adults Aged 18-59

6 months ago talkbio0Tagged Abrysvo, Approved, High-Risk Adults, immunocompromised adults, Pfizer, Respiratory syncytial virus, United States Food and Drug Administration, Vaccines

Pfizer, RSV vaccine, Abrysvo, FDA approval, high-risk adults, immunocompromised adults

Starboard Value Criticizes Pfizer Leadership Over Underperforming R&D and Overpriced Acquisitions

6 months ago talkbio0Tagged Accountability, activist investor, Corporate, Drug Industry, Overpaid M&A Deals, Pfizer, R&D, Starboard Value

Pfizer Inc., Starboard Value, Activist Investor, Pharmaceutical Industry, R&D Underperformance, Overpaid M&A Deals, Corporate Accountability